VACCINATION AGAINST TUMOR-ASSOCIATED HERPESVIRUSES
|
UCLA Technology Available For Licensing |
PREVENTION: Nasopharyngeal carcinoma (NPC), B cell lymphoma,
T cell lymphoma, natural killer cell lymphoma, gastric carcinoma, Kaposi's Sarcoma
(KS) and certain lymphoproliferative disorders are associated with the patient's
prior infection with a herpesvirus (Epstein Barr Virus, EBV or Kaposis sarcoma
associated herpesvirus, KSHV). A preventive vaccination is needed because not
only does herpesviruses establish a life-long latent infection in its host that
can lead to the development of various types of malignancies, reactivation of
the latent virus allows it to be transmitted to new hosts. UCLA researchers have
engineered a herpesvirus deficient in latency. Vaccination with this latency deficient
virus stimulates the immune system against the virus during lytic replication
and protects the host from infection of the wild type virus.
The vaccination strategy developed by UCLA Researchers would therefore achieve the following: 1) prevent the establishment of a latent infection by herpesviruses; 2) protect the host from a predisposition to these disease and malignancies; and 3) prevent the spread of herpesviruses.
RELATED THERAPEUTIC: For patients who have developed malignancies,
this group of researchers has also demonstrated a new mechanism for NF-kB inhibitors
in reactivating virus from latently infected tumor cells, thus enhancing the
efficacy of existing anti-viral agents in killing tumor cells. For the non-confidential
description of this technology, please refer to the following url: http://www.research.ucla.edu/tech/ucla02-479.htm
.
Reference: UCLA Case No. 2003-051
For additional technical details and current licensing
availability,
please contact the following UCLA office:
UCLA Office of Intellectual Property
11000 Kinross Avenue, Suite #200
Los Angeles, CA 90095-7231
Tel: 310-794-0558 Fax: 310-794-0638
email: ncd@research.ucla.edu
|
NCD URL: http://www.research.ucla.edu/tech/ucla03-051.htm
|
UCLA Technologies Available for
Licensing
http://www.research.ucla.edu/tech
Copyright © 2002 The Regents of the
University of California.
keywords: therapeutics prophylactic
uclancd ucla technologies intellectual property patents technology transfer invention business card